SARS-CoV-2 变异株：恢复期血浆、已上市疫苗和单克隆抗体的体外疗效数据概述。
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies.
机构信息
North-Western Tuscany Blood Bank, Pisa University Hospital, Via Paraisa 2, 56124 Pisa, Italy.
Division of Pharmacovigilance, Pisa University Hospital, Via Paradisa 2, 56124 Pisa, Italy.
出版信息
Viruses. 2021 Jun 23;13(7):1211. doi: 10.3390/v13071211.
Abstract
We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.
摘要
在这里，我们总结了恢复期血浆、目前已批准的针对 SARS-CoV-2 变异株（VOC：B.1.1.7、B.1.351、P.1 和 B.1.617.2）、变异株关注（VOI：B.1.427/B.1.429、P.2、B.1.525、P.3、B.1.526 和 B.1.671.1）和其他毒株（B.1.1.298 和 B.1.258delta）的体外疗效证据。在等待真实世界临床疗效的同时，这些数据为治疗医生提供了指导。
相似文献
1
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies.SARS-CoV-2 变异株：恢复期血浆、已上市疫苗和单克隆抗体的体外疗效数据概述。
Viruses. 2021 Jun 23;13(7):1211. doi: 10.3390/v13071211.
2
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
3
Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.SARS-CoV-2 变异株对 COVID-19 恢复期患者体内诱导产生的抗体中和作用的抗性。
Cell Rep. 2021 Jul 13;36(2):109385. doi: 10.1016/j.celrep.2021.109385. Epub 2021 Jun 25.
4
Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.SARS-CoV-2 刺突蛋白的中和抗体逃逸：基于抗体的新冠病毒治疗和疫苗的风险评估。
Rev Med Virol. 2021 Nov;31(6):e2231. doi: 10.1002/rmv.2231. Epub 2021 Mar 16.
5
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
6
Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons.冠状病毒耐药性数据库 (CoV-RDB)：SARS-CoV-2 对单克隆抗体、恢复期血浆和接种者血浆的敏感性。
PLoS One. 2022 Mar 9;17(3):e0261045. doi: 10.1371/journal.pone.0261045. eCollection 2022.
7
The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom.英国流行 SARS-CoV-2 变异株的抗原性。
Front Immunol. 2021 Jun 17;12:687869. doi: 10.3389/fimmu.2021.687869. eCollection 2021.
8
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.恢复期血清和疫苗诱导的抗体对全球 SARS-CoV-2 变体刺突在很大程度上保持中和效价。
mBio. 2021 Jun 29;12(3):e0069621. doi: 10.1128/mBio.00696-21. Epub 2021 Jun 1.
9
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
10
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.SARS-CoV-2 B.1.1.7 对 mRNA 疫苗诱导抗体的敏感性。
Nature. 2021 May;593(7857):136-141. doi: 10.1038/s41586-021-03412-7. Epub 2021 Mar 11.
引用本文的文献
1
A systematic evaluation of the language-of-viral-escape model using multiple machine learning frameworks.使用多个机器学习框架对病毒逃逸模型语言进行的系统评估。
J R Soc Interface. 2025 Apr;22(225):20240598. doi: 10.1098/rsif.2024.0598. Epub 2025 Apr 30.
2
The importance of combining serological testing with RT-PCR assays for efficient detection of COVID-19 and higher diagnostic accuracy.联合使用血清学检测和 RT-PCR 检测对 COVID-19 的高效检测和更高的诊断准确性非常重要。
PeerJ. 2023 Apr 11;11:e15024. doi: 10.7717/peerj.15024. eCollection 2023.
3
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics.生物疗法的工业化趋势：89 种基于抗体的生物疗法产品特征调查。
MAbs. 2023 Jan-Dec;15(1):2191301. doi: 10.1080/19420862.2023.2191301.
4
COVID-19 in Latin America: A Snapshot in Time and the Road Ahead.拉丁美洲的新冠疫情：当下概况与未来之路
Infect Dis Ther. 2023 Feb;12(2):389-410. doi: 10.1007/s40121-022-00748-z. Epub 2023 Jan 12.
5
Probabilistic Approach to COVID-19 Data Analysis and Forecasting Future Outbreaks Using a Multi-Layer Perceptron Neural Network.基于概率方法的COVID-19数据分析及使用多层感知器神经网络预测未来疫情爆发
Diagnostics (Basel). 2022 Oct 19;12(10):2539. doi: 10.3390/diagnostics12102539.
6
B.1.1.7 (Alpha) variant is the most antigenic compared to Wuhan strain, B.1.351, B.1.1.28/triple mutant and B.1.429 variants.与武汉毒株、B.1.351、B.1.1.28/三重突变株和B.1.429变体相比，B.1.1.7（阿尔法）变体的抗原性最强。
Front Microbiol. 2022 Aug 12;13:895695. doi: 10.3389/fmicb.2022.895695. eCollection 2022.
7
Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的单次注射腺相关病毒载体疫苗，具有快速和持久的免疫力。
Acta Pharm Sin B. 2023 May;13(5):2219-2233. doi: 10.1016/j.apsb.2022.07.004. Epub 2022 Jul 12.
8
The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study.康复期血浆疗法治疗新型冠状病毒肺炎重症患者的疗效：一项匹配队列研究
Front Med (Lausanne). 2022 Jun 16;9:822821. doi: 10.3389/fmed.2022.822821. eCollection 2022.
9
COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme.利用高保真 CRISPR-Cas12 酶检测 COVID-19 变体。
J Clin Microbiol. 2022 Jul 20;60(7):e0026122. doi: 10.1128/jcm.00261-22. Epub 2022 Jun 29.
10
Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.由祖先和 B.1.351 AS03 佐剂的重组植物来源的病毒样颗粒疫苗诱导的对 SARS-CoV-2 变体的广泛中和作用。
Vaccine. 2022 Jun 26;40(30):4017-4025. doi: 10.1016/j.vaccine.2022.05.046. Epub 2022 May 27.
本文引用的文献
1
Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant.基于模型对新冠病毒P.1变体的传播性和再感染情况的估计。
Commun Med (Lond). 2021 Nov 15;1:48. doi: 10.1038/s43856-021-00048-6. eCollection 2021.
2
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.LY-CoV1404（贝替洛维单抗）能有效中和 SARS-CoV-2 变体。
Cell Rep. 2022 May 17;39(7):110812. doi: 10.1016/j.celrep.2022.110812. Epub 2022 Apr 25.
3
Extended interval BNT162b2 vaccination enhances peak antibody generation.延长间隔接种BNT162b2疫苗可增强抗体峰值生成。
NPJ Vaccines. 2022 Jan 27;7(1):14. doi: 10.1038/s41541-022-00432-w.
4
Isolation of SARS-CoV-2 B.1.1.28.2 (P2) variant and pathogenicity comparison with D614G variant in hamster model.在仓鼠模型中分离 SARS-CoV-2 B.1.1.28.2 (P2) 变体和与 D614G 变体的致病性比较。
J Infect Public Health. 2022 Feb;15(2):164-171. doi: 10.1016/j.jiph.2021.12.009. Epub 2021 Dec 21.
5
Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity.逃避 SARS-CoV-2 变体刺突表位的识别，但总体上保持 T 细胞免疫。
Sci Transl Med. 2022 Feb 9;14(631):eabj6824. doi: 10.1126/scitranslmed.abj6824.
6
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
7
Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.疫苗诱导产生的抗体水平与针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其变体的中和活性之间的相关性。
Clin Transl Med. 2021 Dec;11(12):e644. doi: 10.1002/ctm2.644.
8
9
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.ChAdOx1 nCoV-19（阿斯利康疫苗）可保护叙利亚仓鼠免受 SARS-CoV-2 B.1.351 和 B.1.1.7 的侵害。
Nat Commun. 2021 Oct 7;12(1):5868. doi: 10.1038/s41467-021-26178-y.
10
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.新出现的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株可逃避感染和疫苗接种所引发的体液免疫反应。
Sci Adv. 2021 Sep 3;7(36):eabj5365. doi: 10.1126/sciadv.abj5365.
Zotero 插件